Skip to main content

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting · Phase 1 · NCT03893955

Conditions: Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors

At a glance

Research payments reported, 2025
$4,065
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
150

About the trial

Sponsor
AbbVie
Tested
ABBV-927 (drug), ABBV-368 (drug), ABBV-181 (drug), Carboplatin (drug), Nab-paclitaxel (drug)
Dates
Started 2019-05-21; completion 2027-03
Results posted
Not yet

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $4,065 in research payments for this study in 2025 (8 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Tennessee Oncology $1,883
  • Highlands Oncology Group PA $1,663
  • Yale University School of Medicine $519

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.